NCT06959693 is a Phase 2, PHASE3 clinical trial of Cetuxima-β in Metastatic Colorectal Cancer (CRC), sponsored by Sun Yat-sen University.

Who is sponsoring NCT06959693?

NCT06959693 is sponsored by Sun Yat-sen University.

What drugs are being tested in NCT06959693?

Interventions in NCT06959693: Cetuxima-β, Envafolimab, mFOLFOX6.

What condition does NCT06959693 study?

NCT06959693 studies Metastatic Colorectal Cancer (CRC).

Is NCT06959693 still recruiting?

NCT06959693 is currently not yet recruiting. Last updated 6 May 2025.

Last reviewed 2025-05-06 · How we verify

NCT06959693

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Clinical Study to Evaluate the Efficacy and Safety of Envafolimab Combined With Cetuxima-βand mFOLFOX6 in Patients With MSS, RAS/BRAF Wild-Type Metastatic Colorectal Cancer (mCRC)

Not yet recruiting Phase 2, PHASE3 Last updated 6 May 2025

What this trial tests

Phase 2, PHASE3 trial testing Cetuxima-β in Metastatic Colorectal Cancer (CRC) in 590 participants. Not yet recruiting.

Timeline

1 June 2025

Primary endpoint
30 September 2028

30 June 2030

Quick facts

Lead sponsor	Sun Yat-sen University
Phase	Phase 2, PHASE3
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	590
Start date	1 June 2025
Primary completion	30 September 2028
Estimated completion	30 June 2030
Sites	1 location across China

Drugs / interventions tested

Cetuxima-β — full drug profile →
Envafolimab — full drug profile →
mFOLFOX6

Conditions studied

Metastatic Colorectal Cancer (CRC) — all drugs for Metastatic Colorectal Cancer (CRC) →

Sponsor

Sun Yat-sen University

Who can join

18 and older, any sex, with Metastatic Colorectal Cancer (CRC). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective randomized controlled Phase Ⅱ/Ⅲ Clinical study to evaluate the clinical efficacy and safety of Envafolimab combining with Cetuximab -β and mFOLFOX6 in Patients With MSS, RAS/BRAF Wild-Type Metastatic Colorectal Cancer (mCRC)

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Metastatic Colorectal Cancer (CRC)

Currently open trials in the same condition.

NCT07228832 — Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer · Phase 3 · recruiting
NCT07167446 — Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy · EARLY_PHASE1 · recruiting
NCT07309289 — NALIRIFOX Plus Targeted Therapy Versus FOLFOX Plus Targeted Therapy as First-line Treatment for Metastatic Colorectal Ca · Phase 3 · recruiting
NCT06958419 — Node-Sparing Short-Course Radiotherapy Plus Chemotherapy, Bevacizumab and PD-1 Inhibitor in Metastatic pMMR/MSS Colorect · Phase 2, PHASE3 · recruiting
NCT06856187 — Second-line Standard Treatment Sequential TAS-102 and Bevacizumab Combined With Local Treatment in Advanced Colorectal C · Phase 2 · recruiting

Other Sun Yat-sen University trials

Trials by the same sponsor.

NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06959693 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
Last refreshed: 6 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06959693.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing